What’s available: 3,000 FDA-approved drugs, countless nutriceuticals and 1000s of devices The Problem: 90% of all patients will not see an effective treatment in their lifetime and for 12,000 diseases, only 30-40 new drugs are approved annually What can be done: With 25 research partners, and less than $7M in philanthropic funds, we have created 9 repurposed treatments changing the lives of thousands of patients What can be done: With 25 research partners, and less than $7M in philanthropic funds, we have created 9 repurposed treatments changing the lives of thousands of patients

 

Cures Within Reach catalyzes repurposing research to quickly and affordably improve patient lives.  Cures Within Reach leverages the speed, safety and cost-effectiveness of medical repurposing research, driving more treatments to more patients more quickly.

REPURPOSING AND COVID19

Repurposing Trials for COVID19:  The global healthcare community is working together in unprecedented ways to treat patients and learn from each other. There are many opportunities underway using already approved drugs in clinical trials to treat COVID19 patients, providing evidence based medicine to clinicians.  Read more about the many clinical repurposing trials at these sites:

  1. BioCentury’s updated table of the 200+ ongoing trials
  2.  ReDo Project led by AntiCancer Fund
  3. Reagan-Udall Foundation for the FDA: COVID19 Treatment Hub as well as its COVID19 Evidence Accelerator

Read past articles about repurposing for COVID19:

  1. The New York Times: 69 drugs to test against COVID19
  2. The Economist: COVID19 and the drugs that might lessen its power

Repurposing Funding Opportunities in COVID19

  1. NCATS: Notice of Special Interest: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease
  2. C3.ai DTI: mitigating COVID with AI  
  3. LifeArc: drug development funding ​

Resources for Repurposing in COVID19​

  1. CURE ID: case reporting tool from NIH/NCATS and FDA ​
  2. Data Against COVID19: data sharing platform  ​
  3. XSEDE’s HPC-COVID19 Consortium: computing resources

 

We serve as a:

Value Driving Catalyst, bringing stakeholders together to undertake repurposing research opportunities; and a

Value Driving Facilitator, building, managing and growing CureAccelerator as a central repurposing platform and creating other opportunities to bring together repurposing research stakeholders

Repurposing tests existing drugs and devices to create treatments for unsolved diseases.  Learn more about repurposing.

  

Submit a proposal for or spread the word about our Open Funding Opportunity Requests for Proposals!

We are currently proposals for cinical and pre-clinical repurposing trials in several disease areas or geographies.  Find more information on our RFP page.

 

CA Live w circleR 2018 v2

CureAccelerator Live! is a philanthropic pitch competition that gives attendees the chance to find and fund the next breakthrough repurposing treatment at a unique networking event for researchers, clinicians, patient groups, biomedical industry professionals and funders. Don’t miss this opportunity to help harness the power of repurposing research and help bring groundbreaking treatments to patients in need. 

 

2020 CureAccelerator Live! for Rare Diseases 

Virtual: June 11 from 3:30-5:30pm ET

CureAccelerator Live! for Rare Diseases is part of the two-day, virtual Rare Drug Development Symposium, organized by Global Genes and Penn Medicine Orphan Disease Center.

Finalists: 

  • Angela Fleischman, MD, PhD, University of California, Irvine: Repurposing a Nutraceutical in Myeloproliferative Neoplasms to Improve Disease Markers and Symptoms
  •  Susanna Park, MD, PhD, University of California, Davis: Bone Marrow Stem Cell Therapy for Vision Loss
  • Tycel Phillips, MD, University of Michigan: Repurposing Venetoclax to Improve Patient Response in Mantle Cell Lymphoma
  • Kathleen Sakamoto, MD, PhD, Stanford University: Niclosamide for the Treatment of Pediatric Acute Myeloid Leukemia
  • Alix Seif, MD, MPH, Children’s Hospital of Philadelphia: Preventing Relapse After Bone Marrow Transplant in a Rare Pediatric Leukemia with a Combination Treatment

 

 

CA Live Rare WinnerCongratulations to the winner of CureAccelerator Live! for Rare Diseases: Kim Nichols, MD, St. Jude Children's Research Hospital "Repurposing a Blood Cancer Drug to Treat an Immune Disorder in Children"

 

 

 

 

CAL DW WinnerCongratulations to the winner of CureAccelerator Live! for the Developing World: Majdi Osman, MD, MPH, OpenBiome "The THRIVE Study: Repurposing Fecal Microbiota Transplantation For the Treatment of Severe Acute Malnutrition in South Africa" - read the full press release here & see photos here.

 

 

 

 

                    

Why is Repurposing important? 

Repurposing101

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*

*required

If the link above doesn't work, please contact our Admin support at admin@cureswithinreach.org with your Full Name and Email Address to sign up!

 

FacebookLinkedinTwitterYoutube
Social Media Icons for Joomla!

Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Wednesday the 3rd. Copyright 2018 Cures Within Reach.